N.Y. postpones opioid bellwether trial as novel coronavirus concerns spread
Drugmakers including Mallinckrodt could push aggressively for a settlement during the New York trial's delay. (Pixabay)
With thousands of opioid lawsuits waiting in the wings, several major drugmakers have been prepping their defenses for a precursor trial slated to begin next week in New York. Now, with the novel coronavirus continuing its spread, those companies face a delay on that trial—which, for them, might be a good thing.
A major New York bellwether opioid trial has been indefinitely postponed "out of an abundance of caution" due to the ongoing outbreak of COVID-19, New York Attorney General Letitia James' office said in a release Tuesday.
The defendants in the New York trial include major players Johnson & Johnson, Allergan, Teva, Purdue, Endo and Mallinckrodt as well as a range of manufacturers, distributors and pharmacies.
De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools
Wednesday, July 8, 2020 | 11am EST / 8am PST
This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.
The decision from Vito C. Caruso, deputy chief administrative judge for courts outside New York City, comes only a week after the court swatted away a defendant request for interim stay, officially slating the trial to begin next week.
James' office said the court would reconvene April 14 "to determine next steps and set a more concrete schedule for trial."